Accuray Incorporated (ARAY) — Analysis Summary
Accuray Incorporated (ARAY) has a market cap of $32.39M with year-over-year revenue growth of +2.7%. Net margin stands at -0.3%. The stock trades at a P/E ratio of -0.7.
Key Takeaways
- Revenue changed +2.7% year-over-year
- Net margin of -0.3%
- P/E ratio of -0.7
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, ARAY posted revenue growth of +2.7% and trades at a P/E of -0.7.
Accuray Incorporated (ARAY)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -1.0x — earnings do not cover interest payments
D/E at 3.5x — high financial leverage
Net income fell 2799.4% vs the prior period.
The latest filing shows negative free cash flow.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
990
Headquarters
MADISON, WI
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.